What's Happening?
Immunome, Inc. will present data from its Phase 3 RINGSIDE trial at the 2026 ASCO Annual Meeting. The trial evaluated varegacestat, a gamma secretase inhibitor, in patients with progressing desmoid tumors. The study, which is the largest of its kind,
assessed progression-free survival and other secondary endpoints such as tumor volume reduction and pain intensity. Positive topline results were reported in December 2025, and Immunome plans to submit a New Drug Application to the FDA in Q2 2026.
Why It's Important?
The RINGSIDE trial represents a significant advancement in the treatment of desmoid tumors, a rare and challenging condition. Varegacestat's potential approval could provide a new therapeutic option for patients who currently have limited treatment choices. The trial's success highlights Immunome's commitment to developing innovative cancer therapies and could pave the way for further research and development in this area.
What's Next?
Following the presentation, Immunome will likely focus on the regulatory submission process for varegacestat, aiming for FDA approval. The company may also explore additional clinical trials to further validate the drug's efficacy and safety. If approved, varegacestat could become a key treatment option for desmoid tumors, potentially improving patient outcomes and quality of life.
